首都医科大学学报 ›› 2026, Vol. 47 ›› Issue (3): 470-481.doi: 10.3969/j.issn.1006-7795.2026.03.008

• 从分子机制到临床应用:创新药物新突破 • 上一篇    下一篇

养血安胎颗粒通过调控铁死亡治疗复发性自然流产:多组学预测与体外实验验证

赵雯,姚伟洁,贡磊磊,盖迪,冯欣*   

  1. 首都医科大学附属北京妇产医院/北京妇幼保健院药事部,北京  100026
  • 收稿日期:2026-02-13 修回日期:2026-03-26 出版日期:2026-06-21 发布日期:2026-06-26
  • 通讯作者: 冯欣 E-mail:fengxin1115@ccmu.edu.cn
  • 基金资助:
    北京市属医院科研培育计划项目(PZ2023029)。

Mechanism of Yangxue Antai granules in treating recurrent spontaneous abortion through ferroptosis regulation: a study integrating multi-omics and experimental

Zhao Wen, Yao Weijie, Gong Leilei, Gai Di, Feng Xin*   

  1. Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University,Beijing Maternal and Child Health Care Hospital, Beijing 100026, China
  • Received:2026-02-13 Revised:2026-03-26 Online:2026-06-21 Published:2026-06-26
  • Supported by:
    This study was supported by Scientific Research Incubating Program Management Project of Beijing Municipal Hospitals(PZ2023029).

摘要: 目的  探讨养血安胎颗粒通过调控铁死亡治疗复发性自然流产(recurrent spontaneous abortion,RSA)的分子机制。方法  运用网络药理学方法,基于中药系统药理学数据库与分析平台(Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform,TCMSP)等数据库筛选养血安胎颗粒的活性成分及其作用靶点,并与从GeneCards、FerrDb等数据库获取的RSA及铁死亡相关的靶点取交集,筛选核心靶点并进行富集分析。采用分子对接验证核心活性成分与靶点的结合能力。通过体外细胞实验进行验证:使用SD大鼠制备养血安胎含药血清;以人绒毛膜癌细胞JEG-3为模型,采用H2O2诱导氧化应激,并给予含药血清干预;最后通过蛋白质印迹法(Western blotting)检测核心靶点TP53、PTGS2及ICAM1的蛋白表达水平。结果  共筛选出88个活性成分、258个药物靶点;获得22个药物-疾病-铁死亡共同靶点,其中ICAM1、TP53、PTGS2为核心靶点;富集分析显示,靶点显著富集于氧化应激、炎症反应及脂质代谢等通路;分子对接证实薯蓣皂苷元、豆甾醇、槲皮素等成分与核心靶点结合良好;体外实验结果表明,与Control组相比,H2O2模型组细胞中TP53、PTGS2及ICAM1蛋白表达均显著升高(均P < 0.01);而与模型组相比,养血安胎含药血清干预可显著抑制三者的蛋白表达(均P < 0.01)。结论 养血安胎颗粒可能通过薯蓣皂苷元、槲皮素等多成分协同,作用于TP53、PTGS2、ICAM1等关键靶点,调控其表达,从而减轻氧化应激与炎症反应,抑制铁死亡,发挥治疗RSA的作用。

关键词: 养血安胎颗粒, 复发性自然流产, 铁死亡, 网络药理学, 分子对接, 蛋白质印迹法

Abstract: Objective  To investigate the molecular mechanism by which Yangxue Antai granules (YXATG) treat recurrent spontaneous abortion (RSA) through the regulation of ferroptosis. Methods  Network pharmacology was employed to screen the active ingredients and potential targets of YXATG by using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and other databases. The obtained targets were intersected with RSA-related and ferroptosis-related targets retrieved from databases such as GeneCards and FerrDb to identify core targets, followed by enrichment analysis. Molecular docking was performed to validate the binding affinity between core active ingredients and the targets. In vitro cell experiments were conducted for verification: drug-containing serum of YXATG was prepared from SD rats; the human choriocarcinoma cell line JEG-3 was used as a model, in which oxidative stress was induced by H2O2 and intervened with the drug-containing serum; finally, Western blotting was used to detect the protein expression levels of the core targets TP53, PTGS2, and ICAM1.Results  A total of 88 active ingredients and 258 drug targets were screened. Twenty-two common targets among YXATG, RSA, and ferroptosis were identified, among which ICAM1, TP53, and PTGS2 emerged as the central targets. Enrichment analysis revealed that the targets were significantly enriched in pathways related to oxidative stress, inflammatory response, and lipid metabolism. Molecular docking confirmed that components such as diosgenin, stigmasterol, and quercetin exhibited good binding affinity to the core targets. In vitro experimental results showed that, compared with the control group, the protein expression levels of TP53, PTGS2, and ICAM1 were significantly increased in the H2O2 model group (all P < 0.01); whereas, compared with the model group, intervention with YXATG-containing serum significantly inhibited the expression of all three proteins (all P < 0.01).Conclusion  YXATG may exert its therapeutic effect on RSA through the synergistic action of multiple components such as diosgenin and quercetin, targeting key molecules including TP53, PTGS2, and ICAM1, regulating their expression, thereby alleviating oxidative stress and inflammatory responses, inhibiting ferroptosis, and ultimately treating RSA.

Key words: Yangxue Antai granules, recurrent spontaneous abortion, ferroptosis, network pharmacology, molecular docking, Western blotting

中图分类号: